Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection.

Mark A. Schnitzler,Robert S. Woodward,Jeffrey A. Lowell,Leah Amir,T. J. Schroeder,Gary G. Singer,Daniel C. Brennan

Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection.

2000

Mark A. Schnitzler
Robert S. Woodward
Jeffrey A. Lowell
Leah Amir
T. J. Schroeder
Gary G. Singer
Daniel C. Brennan

Objective: To evaluate the economic implications for transplant centres, Medicare and society of treatment of corticosteroid-resistant Banff Grades I, II and III acute kidney transplant rejection with the antithymocyte globulins Thymoglobulin® or Atgam®.

Keywords:

Intensive care medicine
Clinical trial
Diagnosis-related group
Renal transplant rejection
Pharmacoeconomics
Confidence interval
Antithymocyte globulins
Thymoglobulin
Medicine
Diabetes mellitus
Kidney transplant rejection
cost analysis
Quality of Life Research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations